Please enable Javascript
Localized Renal Cell Carcinoma
Advertisement
Adjuvant Nivolumab Plus Ipilimumab in Localized RCC: Subgroup Analyses of CheckMate 914
Zachary Bessette
ASCO 2023
|
May 30, 2023
Tumor grade, sarcomatoid features may influence outcomes with adjuvant nivo/ipi in patients with RCC after nephrectomy.
Read More
Evaluating the Safety of Retroperitoneal Laparoscopic Partial Nephrectomy for Localized RCC
Emily Menendez
Localized Renal Cell Carcinoma
|
May 11, 2023
Partial nephrectomy has been gaining traction as an effective treatment for RCC due to its safety and efficacy.
Read More
Using Genomic Sequencing to Refine Risk Prediction for ccRCC
Emily Menendez
Localized Renal Cell Carcinoma
|
April 14, 2023
Tumors with only a VHL mutation were associated with better outcomes compared with tumors containing additional mutations.
Read More
Partial Nephrectomy Versus Percutaneous Ablation for T1a Renal Lesions
Akhil Abraham Saji, MD
Localized Renal Cell Carcinoma
|
March 30, 2023
AUA guidelines for localized RCC have thermal ablation as an alternative modality. EAU guidelines are conflicting.
Read More
Stereotactic Ablative Radiotherapy Is Safe and Effective for Primary Renal Cancer
Emily Menendez
Localized Renal Cell Carcinoma
|
March 23, 2023
SAbR could potentially serve as a new noninvasive alternative treatment, but data on the procedure are limited.
Read More
Reviewing Outcomes and Risk Assessments of Adjuvant Therapy for RCC
Emily Menendez
Localized Renal Cell Carcinoma
|
March 10, 2023
A review of adjuvant therapies shows patient characteristics that may result in favorable treatment responses.
Read More
Improving Functional Outcomes in Localized RCC
Steven Campbell, MD, PhD
ASCO GU Symposium 2023
|
February 18, 2023
Steven Campbell, MD, PhD, overviews the surgical options available for patients with localized renal cell carcinoma.
View More
Trends, Outcomes in Localized RCC With Sarcomatoid Dedifferentiation
Zachary Bessette
ASCO GU Symposium 2023
|
February 17, 2023
Researchers presented the largest retrospective characterization of localized RCC with sarcomatoid dedifferentiation.
Read More
Adjuvant Therapies in RCC: Are New Data Practice Changing?
Matthew Zibelman, MD
ASCO GU Symposium 2023
|
February 16, 2023
Matthew Zibelman, MD, highlights SOC adjuvant therapy for localized RCC and practice-changing potential of novel therapies.
View More
Renal Function for Patients With Oncocytoma Managed With Active Surveillance Versus Partial Nephrectomy
Zachary Bessette
Localized Renal Cell Carcinoma
|
January 20, 2023
A new study evaluated renal function outcomes for patients with oncocytoma managed with surveillance vs nephrectomy.
Read More
Guadecitabine Effectiveness in Patients With HLRCC-Associated RCC, Other Diseases
Zachary Bessette
Localized Renal Cell Carcinoma
|
December 20, 2022
Guadecitabine may be well tolerated in patients with dSDH tumors, including HLRCC-RCC, according to results of a new study.
Read More
Cryoablation Best for Cancer-Specific Mortality in cT1a RCC
Leah Lawrence
Localized Renal Cell Carcinoma
|
December 7, 2022
Cryoablation and heat-based thermal ablation represent alternative management options for frail and/or comorbid RCC patients.
Read More
Radiation for Localized Renal Cell Carcinoma
Akhil Abraham Saji, MD
Journal
|
November 22, 2022
Stereotactic body radiotherapy can benefit RCC patients deemed unfit for surgical therapy.
Read More
Adjuvant Nivolumab/Ipilimumab Did Not Improve DFS in High-Risk Localized RCC
Leah Lawrence
Localized Renal Cell Carcinoma
|
October 18, 2022
Checkmate 914 assigned patients to nivolumab plus ipilimumab or placebo and found no difference in disease-free survival.
Read More
Novel AUA Risk Groups for Localized Renal Cancer Validated by Mayo Clinic Risk Model
GU Oncology Now Editors
SUO Annual Meeting 2021
|
December 2, 2021
Researchers evaluated the new AUA risk stratification system for survival in patients with clear cell or papillary RCC.
Read More
No Value in Surveillance of Pulmonary Recurrence After RCC Resection
GU Oncology Now Editors
AUA 2021
|
September 13, 2021
There is little to no clinical value in surveillance of pulmonary recurrence following resection of T1a renal cell carcinoma.
Read More
Advertisement
Advertisement
Advertisement